Cypris Therapeutics, a pioneering drug discovery company, has officially launched following a breakthrough in synthetic chemistry technology. This innovation enables the development of novel chemistries aimed at treating therapeutically resistant diseases, including brain and pancreatic cancers.
“Our technology represents a new frontier in cancer treatment, offering hope to patients who currently have limited options,” said Kyle Parella, PhD, Co-Founder and CEO of Cypris Therapeutics.
The company’s proprietary technology allows for the synthesis and iteration of complex small molecule moieties previously unattainable by researchers. These molecules are inspired by natural compounds with proven therapeutic properties. Cypris can modify these natural molecules to enhance their therapeutic effects and minimize unwanted side effects. This synthetic chemistry innovation holds the potential to significantly improve the standard of care for patients unresponsive to existing treatments.
Cypris Therapeutics is the latest addition to the portfolio of Ichor Life Sciences, a Syracuse-based contract research organization. Ichor is leading Cypris’s pre-seed funding round, which has already attracted over $500,000. Cypris will incubate at Ichor’s facilities, benefiting from access to state-of-the-art equipment and drug discovery and development expertise.
“We see vast potential in Cypris Therapeutics’ technology, not only as a promising opportunity to develop next-generation oncology treatments but also as a platform for iterating natural products for other age-related conditions where traditional medicinal chemistry approaches have been ineffective,” said Kelsey Moody, PhD, MBA, CEO and Founder of Ichor Life Sciences.
Cypris Therapeutics is steadfast in its commitment to delivering innovative cancer treatments that make a real difference in patients’ lives. As the company advances, it continues to seek additional funding and partnerships to support its ambitious goals.